Inventor · disambiguated record
Charles P. Venditti
Also filed as: VENDITTI CHARLES P
11 granted patents·13 pending applications·28 citations·filing 2009–2024
85Inventor score
Files withUS HEALTH15VENDITTI CHARLES P4LOGICBIO THERAPEUTICS INC1THE UNITED STATE OF AMERICA AS REPRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES1THE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVI1
Top patents by PatentIndex Score
24 records- 0191US9944918B2Synthetic methylmalonyl-CoA mutase transgene for the treatment of MUT class methylmalonic acidemia (MMA)US HEALTH·Filed 2016·Granted Apr 17, 2018·9 cites·11 claims
- 0291US9719080B2Synthetic methylmalonyl-CoA mutase transgene for the treatment of MUT class methylmalonic acidemia (MMA)US HEALTH·Filed 2014·Granted Aug 1, 2017·9 cites·18 claims
- 0386US10307469B2Synthetic methylmalonyl-CoA mutase transgene for the treatment of MUT class methylmalonic acidemia (MMA)US HEALTH·Filed 2017·Granted Jun 4, 2019·3 cites·11 claims
- 0480US2025161383A1Viral gene therapy as treatment for cholesterol storage disease or disorderTHE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVI·Filed 2024·Application pending·0 cites
- 0574US2024409948A1Codon-optimized human npc1 genes for the treatment of niemann-pick type c1 deficiency and related conditionsUS HEALTH·Filed 2024·Application pending·0 cites
- 0672US8721988B2Method for direct measurement of isotopes of expired gasesVENDITTI CHARLES P·Filed 2012·Granted May 13, 2014·2 cites·6 claims
- 0771US8293187B2Device and method for direct measurement of isotopes of expired gasesVENDITTI CHARLES P·Filed 2009·Granted Oct 23, 2012·5 cites·17 claims
- 0870US10894077B2Synthetic methylmalonyl-CoA mutase transgene for the treatment of MUT class methylmalonic acidemia (MMA)US HEALTH·Filed 2019·Granted Jan 19, 2021·0 cites·33 claims
- 0969US12201658B2Viral gene therapy as treatment for cholesterol storage disease or disorderUS HEALTH·Filed 2020·Granted Jan 21, 2025·0 cites·13 claims
- 1060US2025049952A1Improved gene therapy constructs for the treatment of propionic acidemia caused by mutations in propionyl-coa carboxylase alphaUS HEALTH·Filed 2022·Application pending·0 cites
- 1157US2023277688A1Gene therapy for combined methylmalonic acidemia/aciduria and hyperhomocysteinemia/homocystinuria, cobalamin c type, and deficiency of mmachcTHE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVIC·Filed 2022·Application pending·0 cites
- 1256US2023383278A1Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiencyVENDITTI CHARLES P·Filed 2021·Application pending·0 cites
- 1354US12116577B2Codon-optimized human NPC1 genes for the treatment of Niemann-Pick type C1 deficiency and related conditionsTHE UNITED STATE OF AMERICA AS REPRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES·Filed 2018·Granted Oct 15, 2024·0 cites·11 claims
- 1454US2022325266A1Synthetic genes for the treatment of propionic acidemia caused by mutations in propionyl-coa carboxylase betaUS HEALTH·Filed 2020·Application pending·0 cites
- 1554US2023181672A1Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptmsUS HEALTH·Filed 2021·Application pending·0 cites
- 1651US11372004B2Biomarkers of organic acidemiasUS HEALTH·Filed 2018·Granted Jun 28, 2022·0 cites·20 claims
- 1750US11447797B2AAV with unique capsid protein VP1 and methods of using for treatmentUS HEALTH·Filed 2016·Granted Sep 20, 2022·0 cites·12 claims
- 1848US11510998B2Gene therapy for combined methylmalonic acidemia/aciduria and hyperhomocysteinemia/homocystinuria, cobalamin C type, and deficiency of MMACHCUS HEALTH·Filed 2016·Granted Nov 29, 2022·0 cites·14 claims
- 1948US2022251536A1Synthetic genes for the treatment of propionic acidemia caused by mutations in propionyl-coa carboxylase alphaUS HEALTH·Filed 2020·Application pending·0 cites
- 2048US2023390322A1High concentration methylcobalamin or combination of methyl- and hydroxy-cobalamin for the treatment of cobalamin c deficiency disordersUS HEALTH·Filed 2021·Application pending·0 cites
- 2141US2022218843A1Non-disruptive gene therapy for the treatment of mmaLOGICBIO THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2241US2020345268A1Isotopic biomarkers of organic acidemiasVENDITTI CHARLES P·Filed 2018·Application pending·0 cites
- 2341US2018104289A1Viral gene therapy as treatment for cholesterol storage disease or disorderTHE US SECRETARY OF HEALTH AND HUMAN SERVICES·Filed 2016·Application pending·0 cites
- 2438US2018087041A1Tagged form of mut enzyme, genetic constructs incorporating it, and its use in gene thereapyUS HEALTH·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Charles P. Venditti files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →